R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 51.88 CNY 1.63% Market Closed
Market Cap: 5B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one R&G PharmaStudies Co Ltd stock under the Base Case scenario is 59.45 CNY. Compared to the current market price of 51.88 CNY, R&G PharmaStudies Co Ltd is Undervalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
59.45 CNY
Undervaluation 13%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation History
R&G PharmaStudies Co Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
R&G PharmaStudies Co Ltd
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for R&G PharmaStudies Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about R&G PharmaStudies Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

51.88 CNY
+1.63%
+1.63%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

R&G PharmaStudies Co Ltd
CN
Life Sciences Tools & Services
Market Cap
5B CNY
IPO
Aug 2, 2022
Employees
1 926
China
Market Cap
5B CNY
Industry
Life Sciences Tools & Services
IPO
Aug 2, 2022
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about R&G PharmaStudies Co Ltd

Provide an overview of the primary business activities
of R&G PharmaStudies Co Ltd.

What unique competitive advantages
does R&G PharmaStudies Co Ltd hold over its rivals?

What risks and challenges
does R&G PharmaStudies Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for R&G PharmaStudies Co Ltd.

Provide P/S
for R&G PharmaStudies Co Ltd.

Provide P/E
for R&G PharmaStudies Co Ltd.

Provide P/OCF
for R&G PharmaStudies Co Ltd.

Provide P/FCFE
for R&G PharmaStudies Co Ltd.

Provide P/B
for R&G PharmaStudies Co Ltd.

Provide EV/S
for R&G PharmaStudies Co Ltd.

Provide EV/GP
for R&G PharmaStudies Co Ltd.

Provide EV/EBITDA
for R&G PharmaStudies Co Ltd.

Provide EV/EBIT
for R&G PharmaStudies Co Ltd.

Provide EV/OCF
for R&G PharmaStudies Co Ltd.

Provide EV/FCFF
for R&G PharmaStudies Co Ltd.

Provide EV/IC
for R&G PharmaStudies Co Ltd.

Show me price targets
for R&G PharmaStudies Co Ltd made by professional analysts.

What are the Revenue projections
for R&G PharmaStudies Co Ltd?

How accurate were the past Revenue estimates
for R&G PharmaStudies Co Ltd?

What are the Net Income projections
for R&G PharmaStudies Co Ltd?

How accurate were the past Net Income estimates
for R&G PharmaStudies Co Ltd?

What are the EPS projections
for R&G PharmaStudies Co Ltd?

How accurate were the past EPS estimates
for R&G PharmaStudies Co Ltd?

What are the EBIT projections
for R&G PharmaStudies Co Ltd?

How accurate were the past EBIT estimates
for R&G PharmaStudies Co Ltd?

Compare the revenue forecasts
for R&G PharmaStudies Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of R&G PharmaStudies Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of R&G PharmaStudies Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of R&G PharmaStudies Co Ltd compared to its peers.

Compare the P/E ratios
of R&G PharmaStudies Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing R&G PharmaStudies Co Ltd with its peers.

Analyze the financial leverage
of R&G PharmaStudies Co Ltd compared to its main competitors.

Show all profitability ratios
for R&G PharmaStudies Co Ltd.

Provide ROE
for R&G PharmaStudies Co Ltd.

Provide ROA
for R&G PharmaStudies Co Ltd.

Provide ROIC
for R&G PharmaStudies Co Ltd.

Provide ROCE
for R&G PharmaStudies Co Ltd.

Provide Gross Margin
for R&G PharmaStudies Co Ltd.

Provide Operating Margin
for R&G PharmaStudies Co Ltd.

Provide Net Margin
for R&G PharmaStudies Co Ltd.

Provide FCF Margin
for R&G PharmaStudies Co Ltd.

Show all solvency ratios
for R&G PharmaStudies Co Ltd.

Provide D/E Ratio
for R&G PharmaStudies Co Ltd.

Provide D/A Ratio
for R&G PharmaStudies Co Ltd.

Provide Interest Coverage Ratio
for R&G PharmaStudies Co Ltd.

Provide Altman Z-Score Ratio
for R&G PharmaStudies Co Ltd.

Provide Quick Ratio
for R&G PharmaStudies Co Ltd.

Provide Current Ratio
for R&G PharmaStudies Co Ltd.

Provide Cash Ratio
for R&G PharmaStudies Co Ltd.

What is the historical Revenue growth
over the last 5 years for R&G PharmaStudies Co Ltd?

What is the historical Net Income growth
over the last 5 years for R&G PharmaStudies Co Ltd?

What is the current Free Cash Flow
of R&G PharmaStudies Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for R&G PharmaStudies Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
R&G PharmaStudies Co Ltd

Current Assets 2B
Cash & Short-Term Investments 1.7B
Receivables 274.1m
Other Current Assets 63.1m
Non-Current Assets 203.4m
Long-Term Investments 33m
PP&E 55m
Intangibles 105.7m
Other Non-Current Assets 9.7m
Current Liabilities 374.4m
Accounts Payable 49.9m
Accrued Liabilities 43.8m
Short-Term Debt 65.1k
Other Current Liabilities 280.6m
Non-Current Liabilities 64.4m
Long-Term Debt 7.3m
Other Non-Current Liabilities 57.1m
Efficiency

Earnings Waterfall
R&G PharmaStudies Co Ltd

Revenue
738.4m CNY
Cost of Revenue
-447.5m CNY
Gross Profit
291m CNY
Operating Expenses
-172m CNY
Operating Income
119m CNY
Other Expenses
16.1m CNY
Net Income
135.1m CNY

Free Cash Flow Analysis
R&G PharmaStudies Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

R&G PharmaStudies Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive ROIC
62/100
Profitability
Score

R&G PharmaStudies Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

R&G PharmaStudies Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

R&G PharmaStudies Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
R&G PharmaStudies Co Ltd

Wall Street analysts forecast R&G PharmaStudies Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for R&G PharmaStudies Co Ltd is 67.83 CNY with a low forecast of 67.17 CNY and a high forecast of 69.83 CNY.

Lowest
Price Target
67.17 CNY
29% Upside
Average
Price Target
67.83 CNY
31% Upside
Highest
Price Target
69.83 CNY
35% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for R&G PharmaStudies Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for R&G PharmaStudies Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one R&G PharmaStudies Co Ltd stock?

The intrinsic value of one R&G PharmaStudies Co Ltd stock under the Base Case scenario is 59.45 CNY.

Is R&G PharmaStudies Co Ltd stock undervalued or overvalued?

Compared to the current market price of 51.88 CNY, R&G PharmaStudies Co Ltd is Undervalued by 13%.

Back to Top